Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportIn vitro and In vivo Oncology

177Lu-DPI-4452 & 68Ga-DPI-4452, a new radiopeptide tandem targeting Carbonic Anhydrase IX displays strong theranostic potential in CRC and ccRCC tumors

Norbert Wiedemann, Frederic Massiere, Franck Brichory, Inês Borrego, Aileen Hoehne, Frank Osterkamp and Antoine Attinger
Journal of Nuclear Medicine August 2022, 63 (supplement 2) 4048;
Norbert Wiedemann
1Debiopharm International SA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederic Massiere
1Debiopharm International SA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Franck Brichory
2Debiopharm Int.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Inês Borrego
1Debiopharm International SA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aileen Hoehne
33B Pharmaceuticals GmbH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Osterkamp
33B Pharmaceuticals GmbH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoine Attinger
1Debiopharm International SA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 63 no. supplement 2 4048

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online August 8, 2022.

Copyright & Usage 
© 2022

Author Information

  1. Norbert Wiedemann1,
  2. Frederic Massiere1,
  3. Franck Brichory2,
  4. Inês Borrego1,
  5. Aileen Hoehne3,
  6. Frank Osterkamp3 and
  7. Antoine Attinger1
  1. 1Debiopharm International SA
  2. 2Debiopharm Int.
  3. 33B Pharmaceuticals GmbH

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: July 2022 to April 2025

AbstractFullPdf
Jul 2022100
Aug 20221900
Sep 20222300
Oct 20227000
Nov 20225500
Dec 20222400
Jan 20233100
Feb 20235400
Mar 20237600
Apr 20235100
May 20239000
Jun 20237500
Jul 20232100
Aug 20233800
Sep 20234300
Oct 20234000
Nov 20237600
Dec 20237600
Jan 202410000
Feb 202418000
Mar 202415300
Apr 20249500
May 20248500
Jun 202411200
Jul 202424000
Aug 202416200
Sep 202411600
Oct 20249400
Nov 202411400
Dec 20246900
Jan 20256400
Feb 20254800
Mar 20255000
Apr 20255900
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 63, Issue supplement 2
August 1, 2022
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
177Lu-DPI-4452 & 68Ga-DPI-4452, a new radiopeptide tandem targeting Carbonic Anhydrase IX displays strong theranostic potential in CRC and ccRCC tumors
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
177Lu-DPI-4452 & 68Ga-DPI-4452, a new radiopeptide tandem targeting Carbonic Anhydrase IX displays strong theranostic potential in CRC and ccRCC tumors
Norbert Wiedemann, Frederic Massiere, Franck Brichory, Inês Borrego, Aileen Hoehne, Frank Osterkamp, Antoine Attinger
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 4048;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
177Lu-DPI-4452 & 68Ga-DPI-4452, a new radiopeptide tandem targeting Carbonic Anhydrase IX displays strong theranostic potential in CRC and ccRCC tumors
Norbert Wiedemann, Frederic Massiere, Franck Brichory, Inês Borrego, Aileen Hoehne, Frank Osterkamp, Antoine Attinger
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 4048;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Preliminary evaluation of 131I-labeled ITGA5 inhibitor for targeted radionuclide therapy of pancreatic cancer xenografts
  • Immuno-PET using 89Zr-labeled Glypican-1 antibody: a novel theranostic probe for the antibody-drug conjugate treatment in pancreatic cancer
  • The journey to a novel theranostic for prostate cancer : the preclinical study of 64Cu-DOTHA2-PSMA
Show more In vitro and In vivo Oncology

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire